NASDAQ : VTGN
Vistagen Therapeutics, Inc. — Key statistics
Healthcare · Biotechnology · United States
Overview · Financial statements · Key statistics · Dividends · Company profile · Price history · Reports
Key statistics
Valuation
| Measure | Value |
|---|
| Market Cap | 7.43M |
| Enterprise Value | -23.51M |
Dates
| Measure | Value |
|---|
| Earnings Date | Nov 16, 2026 |
| Ex-Dividend Date | n/a |
Shares
| Measure | Value |
|---|
| Current Share Class | 44.38M |
| Shares Outstanding | 44.38M |
| Shares Change (YoY) | +30.85% |
| Shares Change (QoQ) | +1.54% |
| Owned by Insiders (%) | 0.37% |
| Owned by Institutions (%) | 24.95% |
| Float | 41.42M |
Ratios
| Measure | Value |
|---|
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 2.97 |
| Forward PS | 9.91 |
| PB Ratio | 0.30 |
| P/TBV Ratio | 0.30 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Evratios
| Measure | Value |
|---|
| EV / Earnings | n/a |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financialposition
| Measure | Value |
|---|
| Current Ratio | 3.07 |
| Quick Ratio | 2.84 |
| Debt / Equity | 0.03 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | n/a |
Financialefficiency
| Measure | Value |
|---|
| Return on Equity (ROE) | -166.46% |
| Return on Assets (ROA) | -83.21% |
| Return on Invested Capital (ROIC) | -103.20% |
| Return on Capital Employed (ROCE) | -283.86% |
| Weighted Average Cost of Capital (WACC) | 5.48% |
| Revenue Per Employee | $61,000 |
| Profits Per Employee | -$1.65M |
| Employee Count | 41 |
| Asset Turnover | 0.05 |
| Inventory Turnover | n/a |
Taxes
| Measure | Value |
|---|
| Income Tax | 7,000 |
| Effective Tax Rate | n/a |
Stockprice
| Measure | Value |
|---|
| Beta (5Y) | 0.33 |
| 52-Week Price Change | -95.75% |
| 50-Day Moving Average | 0.24 |
| 200-Day Moving Average | 0.44 |
| Relative Strength Index (RSI) | 29.26 |
| Average Volume (20 Days) | 817,755 |
Shortselling
| Measure | Value |
|---|
| Short Interest | 2.47M |
| Short Previous Month | 3.75M |
| Short % of Shares Out | 5.57% |
| Short % of Float | 5.97% |
| Short Ratio (days to cover) | 0.09 |
Incomestatement
| Measure | Value |
|---|
| Revenue | 2.50M |
| Gross Profit | 2.50M |
| Operating Income | -69.67M |
| Pretax Income | -67.61M |
| Net Income | -67.62M |
| EBITDA | -69.46M |
| EBIT | -69.67M |
| Loss Per Share | -$1.66 |
Balancesheet
| Measure | Value |
|---|
| Cash & Cash Equivalents | 31.73M |
| Total Debt | 783,000 |
| Net Cash | 30.95M |
| Net Cash Per Share | $0.70 |
| Equity (Book Value) | 24.48M |
| Book Value Per Share | 0.55 |
| Working Capital | 23.12M |
Cashflow
| Measure | Value |
|---|
| Operating Cash Flow | -62.30M |
| Capital Expenditures | -86,000 |
| Depreciation & Amortization | 211,000 |
| Net Borrowing | -931,000 |
| Free Cash Flow | -62.38M |
| FCF Per Share | -$1.41 |
Margins
| Measure | Value |
|---|
| Gross Margin | 100.00% |
| Operating Margin | -2,785.69% |
| Pretax Margin | -2,703.44% |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends
| Measure | Value |
|---|
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| FCF Payout Ratio | n/a |
| Buyback Yield | -30.85% |
| Shareholder Yield | -30.85% |
| Earnings Yield | -988.59% |
| FCF Yield | -839.26% |
Analystforecasts
| Measure | Value |
|---|
| Price Target | $1.00 |
| Price Target Difference | 497.02% |
| Analyst Consensus | Hold |
| Analyst Count | 4 |
| Revenue Growth Forecast (3Y) | n/a |
| EPS Growth Forecast (3Y) | n/a |
Stocksplits
| Measure | Value |
|---|
| Last Split Date | Jun 7, 2023 |
| Split Type | Reverse |
| Split Ratio | 1:30 |
Scores
| Measure | Value |
|---|
| Altman Z-Score | -21.23 |
| Piotroski F-Score | 2 |
Fairvalue
| Measure | Value |
|---|
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |